Oncocross Signs Three-Way Agreement with April Bio and OmicsAI for Joint New Drug Development
Predicted impact: Low
Three-way joint drug development agreement; no financial terms disclosed.
AprilBio에이프릴바이오
397030 · KOSDAQ · ₩397030 · 에이프릴바이오
₩12,340▼ ₩60 (0.48%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −59.54%
- Market cap
- ₩340B
- Enterprise value
- ₩260B
- P/E
- —
- P/B
- 3.5×
- Dividend yield
- 0.0%
- ROE
- −9.3%
- Net margin
- −1,242.5%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−83.9% from the high
₩11,810Today: ₩12,340 – ₩13,010₩76,700
Returns
- 1W−6.5%
- 1M−31.9%
- 3M−46.0%
- 6M−80.8%
- YTD−77.5%
- 1Y−59.5%
- Volume today
- 88,633
- 0.3× the 20-day average
- Traded today
- ₩1.1B
- Listed shares
- 27,558,782
- EPS (12 months)
- −₩327
- Earnings yield −2.7%
AI research · InitiationAprilBio: Shares Down 55.7% Over a Year as Revenue Fades and Losses PersistThe data shows a company whose 2024 profit proved a one-off against weak results since then, with trailing revenue almost nil, ongoing losses and thin cash, offset by very low debt.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-30.7% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Aug 25: buy ₩86M at the close (1.3% of 20-day average trading value)
On its 29 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 5.8% of trading value and pointed the same way 9 of 29 times.
- 2× KODEX KOSDAQ150 Leverage ₩59M
- -1× KODEX KOSDAQ150 Futures Inverse ₩28M
- 2× TIGER KOSDAQ150 Leverage −₩5.7M
- 2× RISE KOSDAQ150 Futures Leverage ₩3.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
AprilBio stock overview
AprilBio (에이프릴바이오, KRX: 397030) is listed on KOSDAQ, in the Biotech & Pharma sector. April Bio is a Korean research-driven biotech company founded in 2013 as a faculty-startup that develops antibody therapeutics and long-acting recombinant protein drugs. Its shares closed at ₩12,340 on Oct 27, 2026, down 0.48% on the day, giving it a market value of ₩340B.
Key facts
- Market cap
- ₩340B
- Sector
- Biotech & Pharma
- Latest price change
- −0.48%
- As of
- Oct 27, 2026
- Main business
- April Bio is a Korean research-driven biotech company founded in 2013 as a faculty-startup that develops antibody therapeutics and long-acting recombinant protein drugs.
Quick answers about AprilBio
- What does AprilBio do?
- April Bio is a Korean research-driven biotech company founded in 2013 as a faculty-startup that develops antibody therapeutics and long-acting recombinant protein drugs. It relies on its HuDVFab human antibody library and its SAFA platform, which extends the blood half-life of protein drugs by binding serum albumin, and it develops candidates for autoimmune, inflammatory, cancer and rare diseases. The company generates revenue by out-licensing preclinical and early-clinical candidates to global pharmaceutical partners, such as Lundbeck and Evommune, rather than selling approved products.
- What is the market cap of AprilBio?
- The market capitalisation of AprilBio was ₩340B at the close on Oct 27, 2026.
- Who are the largest shareholders of AprilBio?
- According to the latest official filings, the largest reported holders are Cha Sang-hoon (41.30%, as of Oct 23, 2026); TKG Huchems (10.80%, as of Jul 24, 2026); J.P.MORGANSECURITIESPLC (4.83%, as of Dec 10, 2024).
- When is the next earnings report from AprilBio?
- Korean companies rarely announce results dates in advance. Based on when AprilBio filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own AprilBio?
- Yes. The National Pension Service held 0.95% of AprilBio shares as of Dec 31, 2025.
Company profile
April Bio is a Korean research-driven biotech company founded in 2013 as a faculty-startup that develops antibody therapeutics and long-acting recombinant protein drugs. It relies on its HuDVFab human antibody library and its SAFA platform, which extends the blood half-life of protein drugs by binding serum albumin, and it develops candidates for autoimmune, inflammatory, cancer and rare diseases. The company generates revenue by out-licensing preclinical and early-clinical candidates to global pharmaceutical partners, such as Lundbeck and Evommune, rather than selling approved products.
Written by AI from the company's latest annual report.
- Korean name
- 에이프릴바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 차상훈
- Founded
- Jan 2013
- Listed
- Jul 2022
- Listed shares
- 27,558,782
- Fiscal year ends
- Month 12
- Website
- www.aprilbio.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- Amended: Change of largest shareholderOct 23, 2026
- 5%+ holding reportOct 23, 2026
- Investor relations (IR) eventOct 7, 2026
- 5%+ holding reportSep 28, 2026
- Results of Extraordinary Shareholders' MeetingSep 22, 2026
Titles in Korean until English translations are added.
Also known as: AprilBio / 에이프릴바이오 / 397030 / KRX:397030
Source: KRX statistical information